Abstract
Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future. © 2010 Macmillan Publishers Limited All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 1700-1712 |
| Number of pages | 13 |
| Journal | Leukemia |
| Volume | 24 |
| Issue number | 10 |
| DOIs | |
| State | Published - 2010 |
Bibliographical note
Cited By :72Export Date: 3 October 2022
CODEN: LEUKE
Correspondence Address: Terpos, E.; Department of Clinical Therapeutics, 80 Vas. Sofias Avenue, Athens 11528, Greece; email: eterpos@med.uoa.gr
References: Coleman, R.E., Bisphosphonates: Clinical experience (2004) Oncologist, 9 (SUPPL. 4), pp. 14-27; Terpos, E., Dimopoulos, M.A., Myeloma bone disease: Pathophysio-logy and management (2005) Ann Oncol, 16, pp. 1223-1231; Roodman, G.D., Pathogenesis of myeloma bone disease (2009) Leukemia, 23, pp. 435-441; Sezer, O., Myeloma bone disease: Recent advances in biology, diagnosis and treatment (2009) Oncologist, 14, pp. 276-283; Mileshkin, L., Blum, R., Seymour, J.F., Patrikeos, A., Hicks, R.J., Prince, H.M., A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma (2004) Eur J Haematol, 72, pp. 32-37; Dimopoulos, M., Terpos, E., Comenzo, R.L., Tosi, P., Beksac, M., Sezer, O., International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma (2009) Leukemia, 23, pp. 1545-1556; Abildgaard, N., Brixen, K., Eriksen, E.F., Kristensen, J.E., Nielsen, J.L., Heickendorff, L., Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma (2004) Haematologica, 89, pp. 567-577; Terpos, E., Sezer, O., Croucher, P.I., García-Sanz, R., Boccadoro, M., San Miguel, J., The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network (2009) Ann Oncol, 20, pp. 1303-1317; Terpos, E., Dimopoulos, M.A., Sezer, O., The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma (2007) Leukemia, 21, pp. 1875-1884; Von Metzler, I., Krebbel, H., Hecht, M., Manz, R.A., Fleissner, C., Mieth, M., Bortezomib inhibits human osteoclastogenesis (2007) Leukemia, 21, pp. 2025-2034; Calvo, M.S., Eyre, D.R., Gundberg, C.M., Molecular basis and clinical application of biological markers of bone turnover (1996) Endocrine Rev, 17, pp. 333-368; Hannon, R.A., Eastell, R., Biochemical markers of bone turnover and fracture prediction (2003) J Br Menopause Soc, 9, pp. 10-15; Hannon, R.A., Clowes, J.A., Eagleton, A.C., Al Hadari, A., Eastell, R., Blumsohn, A., Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption (2004) Bone, 34, pp. 187-194; Woitge, H.W., Pecherstorfer, M., Horn, E., Keck, A.V., Diel, I.J., Bayer, P., Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma (2001) Br J Cancer, 84, pp. 344-351; Seibel, M.J., Biochemical markers of bone turnover: Part I: Biochemistry and variability (2005) Clin Biochem Rev, 26, pp. 97-122; Delmas, P.D., Bone marker nomenclature (2001) Bone, 28, pp. 575-576; Prockop, D.J., Keiser, H.R., Sjoerdsma, A., Gastrointestinal absorption and renal excretion of hydroxyproline peptides (1962) Lancet, 2, pp. 527-528; Al-Dehaimi, A.W., Blumsohn, A., Eastell, R., Serum galactosyl hydroxylysine as a biochemical marker of bone resorption (1999) Clin Chem, 45, pp. 676-681; Leigh, S.D., Ju, H.S., Lundgard, R., Daniloff, G.Y., Liu, V., Development of an immunoassay for urinary galactosylhydroxylysine (1998) J Immunol Methods, 220, pp. 169-178; Eyre, D.R., Paz, M.A., Gallop, P.M., Cross-linking in collagen and elastin (1984) Annu Rev Biochem, 53, pp. 717-748; Knott, L., Bailey, A.J., Collagen cross-links in mineralizing tissues: A review of their chemistry, function, and clinical relevance (1998) Bone, 22, pp. 181-187; Garnero, P., Ferreras, M., Karsdal, M.A., Nicamhlaoibh, R., Risteli, J., Borel, O., The type i collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation (2003) J Bone Miner Res, 18, pp. 859-867; Hanson, D.A., Weis, M.A., Bollen, A.M., Maslan, S.L., Singer, F.R., Eyre, D.R., A specific immunoassay for monitoring human bone resorption: Quantitation of type i collagen cross-linked N-telopeptides in urine (1992) J Bone Miner Res, 7, pp. 1251-1258; Apone, S., Lee, M.Y., Eyre, D.R., Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone (1997) Bone, 21, pp. 129-136; Bonde, M., Garnero, P., Fledelius, C., Qvist, P., Delmas, P.D., Christiansen, C., Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type i collagen (1997) J Bone Miner Res, 12, pp. 1028-1034; Rosenquist, C., Fledelius, C., Christgau, S., Pedersen, B.J., Bonde, M., Qvist, P., Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type i collagen (1998) Clin Chem, 44, pp. 2281-2289; Risteli, J., Elomaa, I., Niemi, S., Novamo, A., Risteli, L., Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type i collagen: A new serum marker of bone collagen degradation (1993) Clin Chem, 39, pp. 635-640; Sassi, M.L., Eriksen, H., Risteli, L., Niemi, S., Mansell, J., Gowen, M., Immunochemical characterization of assay for carboxyterminal telopeptide of human type i collagen: Loss of antigenicity by treatment with cathepsin K (2000) Bone, 26, pp. 367-373; Janckila, A.J., Takahashi, K., Sun, S.Z., Yam, L.T., Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity (2001) Clinical Chemistry, 47 (1), pp. 74-80; Janckila, A.J., Neustadt, D.H., Nakasato, Y.R., Halleen, J.M., Hentunen, T., Yam, L.T., Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis (2002) Clin Chim Acta, 320, pp. 49-58; Lam, W.K., Eastlund, D.T., Li, C.Y., Yam, L.T., Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children (1978) Clin Chem, 24, pp. 1105-1108; Ylipahkala, H., Halleen, J.M., Kaija, H., Vihko, P., Väänänen, H.K., Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium (2003) Biochem Biophys Res Commun, 308, pp. 320-324; Moss, D.W., Perspectives in alkaline phosphatase research (1992) Clin Chem, 38, pp. 2486-2492; Gallop, P.M., Lian, J.B., Hauschka, P.V., Carboxylated calcium-binding proteins and vitamin K (1980) N Engl J Med, 302, pp. 1460-1466; Nelsestuen, G.L., Shah, A.M., Harvey, S.B., Vitamin K-dependent proteins (2000) Vitam Horm, 58, pp. 355-389; Young, M.F., Kerr, J.M., Ibaraki, K., Heegaard, A.M., Robey, P.G., Structure, expression, and regulation of the major noncollagenous matrix proteins of bone (1992) Clin Orthop Relat Res, 281, pp. 275-294; Sierra, J., Villagra, A., Paredes, R., Cruzat, F., Gutierrez, S., Javed, A., Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity (2003) Mol Cell Biol, 23, pp. 3339-3351; Koeneman, K.S., Kao, C., Ko, S.C., Yang, L., Wada, Y., Kallmes, D.F., Osteocalcin-directed gene therapy for prostate-cancer bone metastasis (2000) World J Urol, 18, pp. 102-110; Christenson, R.H., Biochemical markers of bone metabolism: An overview (1997) Clin Biochem, 30, pp. 573-593; Smedsrod, B., Melkko, J., Risteli, L., Risteli, J., Circulating C-terminal propeptide of type i procollagen is cleared mainly via the mannose receptor in liver endothelial cells (1990) Biochem J, 271, pp. 345-350; Risteli, J., Risteli, L., Assays of type i procollagen domains and collagen fragments: Problems to be solved and future trends (1997) Scand J Clin Lab Invest Suppl, 227, pp. 105-113; Fohr, B., Dunstan, C.R., Seibel, M.J., Clinical review 165: Markers of bone remodeling in metastatic bone disease (2003) J Clin Endocrinol Metab, 88, pp. 5059-5075; Nawawi, H., Samson, D., Apperley, J., Girgis, S., Biochemical bone markers in patients with multiple myeloma (1996) Clin Chim Acta, 253, pp. 61-77; Abildgaard, N., Bentzen, S.M., Nielsen, J.L., Heickendorff, L., Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type i collagen (ICTP) (1997) Br J Haematol, 96, pp. 103-110; Withold, W., Arning, M., Schwarz, M., Wolf, H.H., Schneider, W., Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation (1998) Clin Chim Acta, 269, pp. 21-30; Carlson, K., Larsson, A., Simonsson, B., Turesson, I., Westin, J., Ljunghall, S., Evaluation of bone disease in multiple myeloma: A comparison between the resorption markers urinary deoxypyridinoline/creati-nine (DPD) and serum ICTP, and an evaluation of the DPD/ osteocalcin and ICTP/osteocalcin ratios (1999) Eur J Haematol, 62, pp. 300-306; Woitge, H.W., Pecherstorfer, M., Li, Y., Keck, A.V., Horn, E., Ziegler, R., Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices (1999) J Bone Miner Res, 14, pp. 792-801; Fonseca, R., Trendle, M.C., Leong, T., Kyle, R.A., Oken, M.M., Kay, N.E., Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients (2000) Br J Haematol, 109, pp. 24-29; Terpos, E., Palermos, J., Tsionos, K., Anargyrou, K., Viniou, N., Papassavas, P., Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma (2000) Eur J Haematol, 65, pp. 331-336; Woitge, H.W., Horn, E., Keck, A.V., Auler, B., Seibel, M.J., Pecherstorfer, M., Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis (2001) Clin Chem, 47, pp. 686-693; Corso, A., Arcaini, L., Mangiacavalli, S., Astori, C., Orlandi, E., Lorenzi, A., Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients (2001) Haematologica, 86, pp. 394-398; Jakob, C., Zavrski, I., Heider, U., Brux, B., Eucker, J., Langelotz, C., Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma (2002) Eur J Haematol, 69, pp. 37-42; Alexandrakis, M.G., Passam, F.H., Malliaraki, N., Katachanakis, C., Kyriakou, D.S., Margioris, A.N., Evaluation of bone disease in multiple myeloma: A correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients (2002) Clin Chim Acta, 325, pp. 51-57; Abildgaard, N., Brixen, K., Kristensen, J.E., Eriksen, E.F., Nielsen, J.L., Heickendorff, L., Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy (2003) Br J Haematol, 120, pp. 235-242; Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index (2003) Blood, 102, pp. 1064-1069; Terpos, E., De La Fuente, J., Szydlo, R., Hatjiharissi, E., Viniou, N., Meletis, J., Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma (2003) Int J Cancer, 106, pp. 455-457; Coleman, R.E., Major, P., Lipton, A., Brown, J.E., Lee, K.A., Smith, M., Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid (2005) J Clin Oncol, 23, pp. 4925-4935; Kuliszkiewicz-Janus, M., Máecki, R., Zótaszek, A., Zastawny, M., The significance of carboxy-terminal telopeptide of type i collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma (2005) Leuk Lymphoma, 46, pp. 1749-1753; Dizdar, O., Barista, I., Kalyoncu, U., Karadag, O., Hascelik, G., Cila, A., Biochemical markers of bone turnover in diagnosis of myeloma bone disease (2007) Am J Hematol, 82, pp. 185-191; Jakob, C., Sterz, J., Liebisch, P., Mieth, M., Rademacher, J., Goerke, A., Incorporation of the bone marker carboxy-terminal telopep-tide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma (2008) Leukemia, 22, pp. 1767-1772; Terpos, E., Palermos, J., Viniou, N., Vaiopoulos, G., Meletis, J., Yataganas, X., Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment (2001) Calcif Tissue Int, 68, pp. 285-290; Clark, R.E., Flory, A.J., Ion, E.M., Woodcock, B.E., Durham, B.H., Fraser, W.D., Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma (2000) Blood, 96, pp. 2697-2702; Terpos, E., Politou, M., Szydlo, R., Nadal, E., Avery, S., Olavarria, E., Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma (2004) Leukemia, 18, pp. 1420-1426; Abildgaard, N., Glerup, H., Rungby, J., Bendix-Hansen, K., Kassem, M., Brixen, K., Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma (2000) Eur J Haematol, 64, pp. 121-129; Jakob, C., Zavrski, I., Heider, U., Bollow, M., Schulz, C.O., Fleissner, C., Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography (2003) Clin Cancer Res, 9, pp. 3047-3051; Alexandrakis, M.G., Kyriakou, D.S., Passam, F.H., Malliaraki, N., Vlachonikolis, I.G., Karkavitsas, N., Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity (2003) Hematol Oncol, 21, pp. 17-24; Terpos, E., Berenson, J., Cook, R.J., Lipton, A., Coleman, R.E., Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease (2010) Leukemia, 24, pp. 1043-1049; Turesson, I., Abildgaard, N., Ahlgren, T., Dahl, I., Holmberg, E., Hjorth, M., Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors (1999) Br J Haematol, 106, pp. 1005-1012; Schütt, P., Rebmann, V., Brandhorst, D., Wiefelspütz, J., Ebeling, P., Opalka, B., The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients (2008) Hum Immunol, 69, pp. 79-87; Terpos, E., Berenson, J., Lipton, A., Coleman, R., Cook, R., High baseline NTX predicts for inferior survival and shorter time to first SRE in Multiple Myeloma (2009) Clin Lymphoma Myeloma, 9 (SUPPL. 1), pp. 50-51; Elomaa, I., Risteli, L., Laakso, M., Lahtinen, R., Virkkunen, P., Risteli, J., Monitoring the action of clodronate with type i collagen metabolites in multiple myeloma (1996) Eur J Cancer, 32 A, pp. 1166-1170; Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases (2001) Cancer, 91, pp. 1191-1200; Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., MacKey, J., Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial (2001) Cancer J, 7, pp. 377-387; Menssen, H.D., Sakalov, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma (2002) J Clin Oncol, 20, pp. 2353-2359; Terpos, E., Viniou, N., De La Fuente, J., Meletis, J., Voskaridou, E., Karkantaris, C., Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-micro-globulin in multiple myeloma (2003) Eur J Haematol, 70, pp. 34-42; Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteo-protegerin ratio (2005) Leukemia, 19, pp. 1969-1976; Lipton, A., Cook, R.J., Coleman, R.E., Smith, M.R., Major, P., Terpos, E., Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma (2007) Clin Lymphoma Myeloma, 7, pp. 346-353; Henry, D., Von Moos, R., Vadhan-Raj, S., Hungria, V., Spencer, A., Hirsh, V., A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma (2009) Eur J Cancer, (SUPPL. 3), p. 12. , (abstract 20LBA); Seidel, C., Hjertner Ø, Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease (2001) Blood, 98, pp. 2269-2271; Lipton, A., Ali, S.M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Serum osteoprotegerin levels in healthy controls and cancer patients (2002) Clin Cancer Res, 8, pp. 2306-2310; Goranova-Marinova, V., Goranov, S., Pavlov, P., Tzvetkova, T., Serum levels of OPG RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations (2007) Haemato-logica, 92, pp. 1000-1001; Martini, G., Gozzetti, A., Gennari, L., Avanzati, A., Nuti, R., Lauria, F., The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma (2006) Haematologica, 91, pp. 1720-1721; Terpos, E., Kastritis, E., Roussou, M., Heath, D., Christoulas, D., Anagnostopoulos, N., The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (2008) Leukemia, 22, pp. 2247-2256; Kraj, M., Owczarska, K., Sokołowska, U., Centkowski, P., Pogłód, R., Kruk, B., Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients (2005) Arch Immunol Ther Exp, 53, pp. 454-464; Nanci, A., Content and distribution of noncollagenous matrix proteins in bone and cementum: Relationship to speed of formation and collagen packing density (1999) J Struct Biol, 126, pp. 256-269; Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma (2003) N Engl J Med, 349, pp. 2483-2494; Politou, M.C., Heath, D.J., Rahemtulla, A., Szydlo, R., Anagnostopoulos, A., Dimopoulos, M.A., Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation (2006) Int J Cancer, 119, pp. 1728-1731; Kaiser, M., Mieth, M., Liebisch, P., Oberländer, R., Rademacher, J., Jakob, C., Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma (2008) Eur J Hematol, 80, pp. 490-494; Haaber, J., Abildgaard, N., Knudsen, L.M., Dahl, I.M., Lodahl, M., Thomassen, M., Myeloma cell expression of 10 candidate genes for osteolytic bone disease. only overexpression of DKK1 correlates with clinical bone involvement at diagnosis (2008) Br J Haematol, 140, pp. 25-35; Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., Shaughnessy Jr., J.D., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo (2007) Blood, 109, pp. 2106-2111; Tosi, P., Zamagni, E., Cellini, C., Parente, R., Cangini, D., Tacchetti, T., First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma (2006) Eur J Haematol, 76, pp. 399-404; Breitkreutz, I., Raab, M.S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) Leukemia, 22, pp. 1925-1932; Zangari, M., Esseltine, D., Lee, C.-K., Barlogie, B., Elice, F., Burns, M.J., Kang, S.-H., Tricot, G., Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma (2005) British Journal of Haematology, 131 (1), pp. 71-73. , DOI 10.1111/j.1365-2141.2005.05733.x; Zangari, M., Yaccoby, S., Cavallo, F., Esseltine, D., Tricot, G., Response to bortezomib and activation of osteoblasts in multiple myeloma (2006) Clinical Lymphoma and Myeloma, 7 (2), pp. 109-114; Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C.O., Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment (2006) Eur J Haematol, 77, pp. 233-238; Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients (2007) Blood, 110, pp. 334-338; Terpos, E., Heath, D.J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand co ncentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma (2006) Br J Haematol, 135, pp. 688-692
Keywords
- bone markers
- CTX
- ICTP
- myeloma
- NTX
- amino terminal telopeptide
- biochemical marker
- carboxy terminal telopeptide
- matrix metalloproteinase
- bone atrophy
- bone destruction
- bone disease
- bone remodeling
- bone turnover
- disease activity
- disease course
- early diagnosis
- human
- morbidity
- multiple myeloma
- ossification
- osteolysis
- overall survival
- priority journal
- review
